Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer

K. Margolin, S. Akman, B. Carr, L. Leong, J. Doroshow

Research output: Contribution to journalArticlepeer-review


Seventeen patients with small-cell lung cancer refractory to combination chemotherapy were entered in a study of VP-16 and infusional Ara-C. All patients were evaluable for response and 14 were evaluable for toxicity (three deaths that occurred after the first cycle of therapy were due to progressive tumor, and toxicity could not be evaluated in these three patients). Ara-C was given as a continuous intravenous infusion of 45 mg/m2/day for 72 h; VP-16 was given as three daily intravenous bolus doses of 50 mg/m2 at hours 12, 36, and 50 of the 72-h Ara-C infusion. Because of excessive myelotoxicity in the first six patients, the last 11 patients began treatment at a lower dose of Ara-C, 25 mg/m2/day. Six of 17 patients had previously been exposed to VP-16 as part of their initial chemotherapy regimen. The 17 patients received 32 cycles of therapy. Myelotoxicity was severe, with nadir granulocyte counts

Original languageEnglish
Pages (from-to)499-501
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number4
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer'. Together they form a unique fingerprint.

Cite this